Metrics as of 10/16/2026, 08:34 AM (Berlin time), refresh in progress.
Theriva Biologics Stock
Theriva Biologics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Steven A. Shallcross
- Employees
- 16
- Market cap
- $10 M
- IPO
- 18/12/2006
Theriva Biologics Inc. is a clinical-stage biotechnology firm dedicated to developing novel treatments for conditions with significant unmet medical needs. The company's pipeline features several promising candidates, including SYN-004, which is engineered to break down commonly used intravenous beta-lactam…
Theriva Biologics stock: price history
1D
+1.0%
1W
-6.6%
1M
-5.8%
6M
-16.0%
YTD
+0.8%
1Y
-74.8%
2Y
-84.7%
5Y
-99.8%
10Y
-100.0%
Next earnings date
Next earnings date
17/11/2026 (in 31 days)
Volatility around earnings
~6% weaker price swings than usual
Ask the agents about Theriva Biologics
Analyst assessment of Theriva Biologics
0
STRONG BUY
1
BUY
0
HOLD
0
SELL
0
STRONG SELL
1
TOTAL · Buy
As of: 31/03/2026
Theriva Biologics stock metrics
P/E
-0.32
P/B
0.8
EV/EBITDA
-0.17
RETURN ON EQUITY
-26.4%
NET MARGIN
0.0%
DEBT/EQUITY
0.29
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
98.4%
FLOAT SHARES
45,143,241
AVG. DAILY VOLUME (30D)
504,383
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Theriva Biologics stock
What does Theriva Biologics do?
Theriva Biologics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Steven A. Shallcross, the company employs around 16 people.
The IPO was on 18/12/2006; the stock trades on AMEX under the ticker TOVX.
What do analysts say about Theriva Biologics stock?
1 analysts rate the stock, the consensus is Buy (as of 31/03/2026).
This is an external assessment, not a statement by Market Jury.
When does Theriva Biologics report next?
The next earnings date is 17/11/2026.
Around past earnings, price swings were roughly -6% stronger than usual.
Does Theriva Biologics pay a dividend?
No, Theriva Biologics currently does not pay a dividend.
Which stocks are comparable to Theriva Biologics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Theriva Biologics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Theriva Biologics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.